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Lentivirus-meditated frataxin gene delivery reverses genome
instability in Friedreich ataxia patient and mouse model
ﬁbroblasts
H Khonsari1,2, M Schneider1,2, S Al-Mahdawi1,2, YG Chianea1,2, M Themis1, C Parris1, MA Pook1,2 and M Themis1,2,3
Friedreich ataxia (FRDA) is a progressive neurodegenerative disease caused by deﬁciency of frataxin protein, with the primary sites
of pathology being the large sensory neurons of the dorsal root ganglia and the cerebellum. FRDA is also often accompanied by
severe cardiomyopathy and diabetes mellitus. Frataxin is important in mitochondrial iron–sulfur cluster (ISC) biogenesis and low-
frataxin expression is due to a GAA repeat expansion in intron 1 of the FXN gene. FRDA cells are genomically unstable, with
increased levels of reactive oxygen species and sensitivity to oxidative stress. Here we report the identiﬁcation of elevated levels of
DNA double strand breaks (DSBs) in FRDA patient and YG8sR FRDA mouse model ﬁbroblasts compared to normal ﬁbroblasts. Using
lentivirus FXN gene delivery to FRDA patient and YG8sR cells, we obtained long-term overexpression of FXN mRNA and frataxin
protein levels with reduced DSB levels towards normal. Furthermore, γ-irradiation of FRDA patient and YG8sR cells revealed
impaired DSB repair that was recovered on FXN gene transfer. This suggests that frataxin may be involved in DSB repair, either
directly by an unknown mechanism, or indirectly via ISC biogenesis for DNA repair enzymes, which may be essential for the
prevention of neurodegeneration.
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INTRODUCTION
Friedreich ataxia (FRDA) is an autosomal recessive inherited
neurodegenerative disorder for which there is no known effective
treatment or cure. Neurodegeneration is accompanied by cardiac
hypertrophy and heart failure, which is the main cause of mortality
usually at ~ 40 years of age.1 It is the most common hereditary
ataxia with a prevalence of 1 in 29 000 in the Caucasian
population and a carrier frequency of 1 in 85.2 Neurological
symptoms include gait ataxia, dysarthria, ﬁxation instability, loss of
joint and vibratory senses, loss of tendon reﬂexes, abnormal
Babinski sign and muscle weakness. Patients lose the ability to
stand and walk within 10–15 years of onset and soon become
wheelchair bound.3
Neurodegenerative pathology occurs primarily in the large
sensory neurons of the dorsal root ganglia and cerebellum.4 In
96% of patients with FRDA, a homozygous GAA triplet repeat
expansion is found in the ﬁrst intron of the frataxin (FXN) gene.
The triplet repeat size correlates directly with the severity of the
disease phenotype and inversely with the age of onset.2 The
expansion leads to epigenetic changes and heterochromatic-
silencing of the FXN gene.5 Reduced expression of frataxin leads to
impaired electron transport chain (ETC) function, which is
accompanied by oxidative stress. Frataxin-deﬁcient cells are highly
sensitive to oxidative stress and have reduced capability to handle
oxidative insults.6 The exact function of frataxin is not fully
understood. Frataxin processing involves a transient intermediate
form (FXN 42-210) and a mature form (FXN 81-210) of the protein
that have been both identiﬁed in the cytoplasm and mitochondria
of cells. Only the mature form is understood to be transported to
the mitochondrion7, which is known to be essential for iron
homeostasis, in particular for the de novo biosynthesis of iron–
sulfur cluster (ISC) proteins and heme biosynthesis.8 It is thereby
involved in activation of the tricarboxylic cycle enzyme aconitase,
which can be used as an indicator of low levels of frataxin protein
and mitochondrial damage.6 Deﬁciency in frataxin results in
impaired biosynthesis and the function of ISC proteins of the ETC,
leading to reduced adenosine triphosphate and energy
production.9 Cells highly dependent on aerobic respiration and
high adenosine triphosphate levels, such as neurons in the brain
and spinal cord, cardiomyocytes and pancreatic beta cells,
especially succumb to this imbalance in energy homeostasis and
this is believed to cause the neurological and cardiac symptoms
and the high prevalence of diabetes in patients. However, what
causes the variable cell death within tissues is still unclear.10
Oxidative stress is known to be associated with genome
instability,11 and in FRDA cells that have decreased frataxin
expression, reduced capacity for DNA damage repair is evident.8,12
Differential expression of genes associated with genotoxicity
stress, including oxidative phosphorylation, has also been found in
peripheral blood mononuclear cells of FRDA patients, where
mitochondrial and nuclear DNA damage is increased.13 In the
yeast model of FRDA, reduced levels of frataxin correlate with DNA
damage and recombination, mutation events and genome
instability. These cells are also highly sensitive to DNA-damaging
agents.14 Low-frataxin expression is associated with increased
sensitivity to ionizing radiation,15 whereas high-frataxin expression
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correlates with reduced levels of mitochondrial reactive oxygen
species. It is unclear whether low-frataxin expression leading to
high levels of reactive oxygen species and DNA damage is the
only cause of neuronal degeneration. Recently, however, the role
of frataxin in DNA repair has been suggested to involve MUTYH
and PARP 1 gene expression with low-FXN expression being
associated with microglial DNA damage.16 Interestingly, over-
expression of frataxin by ninefolds has also been reported to be
deleterious to life span, impair locomotor ability and cause brain
damage in a Drosophila model of FRDA,17 and this would suggest
any gene therapy approach to correct FRDA would require strict
control of frataxin gene expression.18 Overexpression of human
frataxin in transgenic mice by up to tenfolds has been shown to
have no deleterious effects.19 Furthermore, in a recent gene
therapy study, correction of the FRDA heart pathology of the Mck
conditional knockout mouse model with complete frataxin
deletion in cardiac and skeletal muscle was achieved where
frataxin was overexpressed tenfold over that of endogenous
frataxin, without deleterious side effects in the corrected mice.20
Because sensory neurones are difﬁcult to obtain and may not
survive long-term in culture, in this study, we have used FRDA
patient ﬁbroblasts (GM03665, 445 and 740 GAA repeats) and
ﬁbroblasts of the YG8sR mouse model that carries 120 GAA
repeats in intron 1 of a human FXN transgene to investigate
correction of FRDA by lentivirus vectors (LVs). FRDA ﬁbroblasts
have been shown useful to model this disease as they display
FRDA characteristics and are readily available. They have increased
mitochondrial sensitivity to oxidative stress and respond to
treatments that reduce oxidative stress and improve cell
viability.21–23 They have also been shown amenable to partial
correction using FXN-carrying adeno-associated virus and LV gene
therapy vectors.24 LVs were chosen because these vectors can
transduce most cell types, especially neuronal cells to provide
permanent gene expression. To examine for the potential of
deleterious effects on cells caused by high-frataxin gene expres-
sion, we used the strong spleen focus-forming virus (SFFV)
promoter internally to self-inactivating (SIN) long terminal repeats
to drive frataxin expression. Following robust FXN gene transfer,
we measured the effects of high FXN gene expression on oxidative
stress and genome instability using the γ-H2AX histone variant
marker, which is recruited to DNA double strand breaks (DSBs). We
next challenged FRDA ﬁbroblasts with γ-radiation-induced DNA
damage and proﬁled the DNA damage-repair potential in
lentivirus FXN-treated versus untreated cells. We found that
high-level FXN gene expression restores cell viability, reduces
genome instability and improves the DNA damage-repair
potential of these cells close to the levels found in normal
ﬁbroblasts. These data suggest that LV gene therapy may offer a
permanent correction to FRDA.
RESULTS
LV infection of FRDA ﬁbroblasts is efﬁcient and permanent
Human and YG8sR mouse model FRDA ﬁbroblasts were exposed
to two rounds of pHR’SIN-cPPT-SFFV-green ﬂuorescent protein
eGFP-WPRE LV infection each at an multiplicity of infection of 10
to achieve 92 and 97% positive eGFP expressing cells, respectively,
as determined by light microscopy and ImageStream (Amnis Inc.,
Seattle, WA, USA) ﬂow cytometry (Supplementary Figure 1). After
8 weeks, human (GMO3665) and mouse (YG8sR) ﬁbroblasts were
once again examined for positive eGFP expression that remained
in 88 and 93% of cells, respectively, demonstrating stable LV
integration. Next, pHR’SIN-cPPT-SFFV-FXN-WPRE and pHR’SIN-
cPPT-SFFV-eGFP-WPRE vector copy numbers were established at
48 h and then again at 8 weeks after infection. pHR’SIN-cPPT-SFFV-
eGFP-WPRE showed a higher copy number in the mouse
ﬁbroblasts at 2 copies per cell versus 1 copy per cell in the
human ﬁbroblasts, whereas the vector copy numbers of pHR’SIN-
cPPT-SFFV-FXN-WPRE for both species appeared at 1 copy per cell
and remained so after 8 weeks in culture (Supplementary
Figure 2).
FXN gene and frataxin protein expression persist over time
We next measured FXN gene expression in pHR’SIN-cPPT-SFFV-
FXN-WPRE-infected cells using quantitative real-time PCR (qRT-
Figure 1. (a, b) FXN gene expression in FRDA ﬁbroblasts. (a) Human,
(b) Mouse. qRT-PCR quantiﬁcation of FXN transgene expression after
pHR’SIN-cPPT-SFFV-FXN-WPRE infection of ﬁbroblasts 2, 8 and
12 weeks post infection. Cells infected with pHR’SIN-cPPT-SFFV-
eGFP-WPRE served as controls. After normalizing to endogenous
GAPDH gene expression, FXN expression in the human and mouse
FRDA cells reached 96- and 210-fold, respectively after infection
compared with uninfected FRDA cells and 0.5- and 0.2-fold,
respectively, compared with normal ﬁbroblasts. Over time, this
expression appeared to fall by ~ 50%, however FXN expression
remained signiﬁcantly greater than in untreated FRDA ﬁbroblasts
over the 12-week-period after gene delivery. Control normal human
ﬁbroblasts=GMO7492, FRDA ﬁbroblasts=GMO3665. Control nor-
mal mouse model ﬁbroblasts=Y47, FRDA ﬁbroblasts=YG8sR. The
data shown is the mean of two independent experiments where
n= 3/experiment. Error bars represent the standard error of the
means s.e.m. Signiﬁcance differences are represented by asterisks:
*Po0.05, **Po0.01 and ***Po0.001.
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PCR) at 2, 8 and 12 weeks post infection compared with
uninfected cells and control normal human and mouse ﬁbroblasts
to determine levels and longevity of gene expression. After
normalizing to endogenous GAPDH gene expression, FXN expres-
sion in the human and mouse FRDA cells reached 96- and 210-
fold, respectively, after infection, compared with uninfected FRDA
cells 0.5- and 0.2-fold, respectively, compared with normal
ﬁbroblasts. Over time, this expression appeared to fall by ~ 50%,
but FXN expression remained signiﬁcantly greater than in
untreated FRDA ﬁbroblasts over the 12-week-period after gene
delivery (Figure 1). We measured frataxin protein levels in the
human and mouse ﬁbroblasts using lateral ﬂow immunoassay.
Frataxin levels of pHR’SIN-cPPT-SFFV-FXN-WPRE-infected cells
increased to 42- and 17-fold, respectively, compared with
untreated FRDA cells and 0.48- and 0.2-fold, respectively, to that
of normal ﬁbroblasts. Frataxin protein levels also decreased in
both the human and mouse ﬁbroblasts over time. However,
protein levels remained signiﬁcantly higher than untreated FRDA
ﬁbroblasts (Figure 2).
Localization of frataxin isoforms to subcellular compartments
Frataxin protein processing involves the production of a transient
intermediate form and the fully mature form, of which the latter is
known to localize to mitochondria. Fibroblast cells treated with
pHR’SIN-cPPT-SFFV-FXN-WPRE and treated with pHR’SIN-cPPT-
SFFV-eGFP-WPRE along with untreated YG8sR mouse model and
human patients, and control normal ﬁbroblasts were fractionated
to isolate mitochondria, nuclei and cytoplasmic fractions. Each
fraction was subjected to western analysis for the presence of
these forms using a primary antibody and secondary-HRP-
conjugated antibody to identify both intermediate and mature
human and mouse forms of frataxin. As expected, high-frataxin
protein levels were found in the mitochondria in the 14 kDa
mature form. In the cytoplasm, the 19 kDa transient inter-
mediate form was also identiﬁed. In addition, a weak band
representing the mature form was identiﬁed in the normal control
mouse ﬁbroblast nuclei and a stronger band was found in the
nuclei of the mouse FRDA ﬁbroblasts treated with pHR’SIN-cPPT-
SFFV-FXN-WPRE (Figure 3). Neither the intermediate nor mature
forms were observable in the nuclei of human patient and healthy
ﬁbroblasts.
FXN gene transfer increases aconitase activity
Because aconitase enzyme activity can be used as an indicator of
low levels of frataxin protein, we examined the activity of this
enzyme in both sets of treated ﬁbroblasts (Figure 4). We found
that the aconitase activity for the treated human and mouse
ﬁbroblasts reached 103 and 116% of the levels found in normal
ﬁbroblasts, respectively, compared with original levels of 68 and
49%, respectively, in untreated FRDA cells. This suggests that FXN
gene transfer can restore normal activity of this vital tricarboxylic
acid enzyme.
High FXN expression is not deleterious to FRDA ﬁbroblast growth
and cell survival
A high level of FXN gene expression has been previously reported
to be cytotoxic,18 which would make gene therapy of FRDA
problematic. As we achieved high-level FXN expression in both
human and mouse ﬁbroblasts without observable adverse effects,
we chose to evaluate cell survival and population doubling times
of untreated versus pHR’SIN-cPPT-SFFV-eGFP-WPRE vector-treated
cells next to control ﬁbroblasts. Following 45 days of culture
growth, population doublings for FXN-treated human and mouse
FRDA cells appeared unaffected in both treated populations. Cell
survival also improved, as identiﬁed by clonogenic cell survival assay
(Po0.001) in contrast to pHR’SIN-cPPT-SFFV-eGFP-WPRE-treated
and untreated FRDA cells (Supplementary Figure 3). This demon-
strated that no adverse effects were caused by LV-mediated high
FXN gene expression.
Oxidative stress is reduced by FXN gene delivery
We next investigated levels of protein oxidation as a measure of
oxidative stress in FRDA cells using the Oxyblot kit immuno-
detection and quantiﬁcation assay. We found levels of oxidative
stress in human and mouse FRDA ﬁbroblasts to be signiﬁcantly
greater than in normal ﬁbroblasts (nearly twofold increased).
Following pHR’SIN-cPPT-SFFV-FXN-WPRE gene transfer, the level
Figure 2. (a, b) Frataxin protein levels in infected ﬁbroblasts.
(a) Human; (b) Mouse. Quantiﬁcation of FXN protein expression
after pHR’SIN-cPPT-SFFV-FXN-WPRE LV infection of ﬁbroblasts 2, 8
and 12 weeks post infection. Cells infected with pHR’SIN-cPPT-SFFV-
eGFP-WPRE served as controls. Frataxin protein was extracted from
ﬁbroblasts and used for a lateral ﬂow immunoassay (‘dipstick’ assay).
Frataxin levels of infected human and mouse cells increased as
expected to 42- and 17-fold, respectively, compared with untreated
FRDA cells 0.48- and 0.2-fold, respectively, of normal ﬁbroblasts.
Frataxin protein levels also decreased in both human and mouse
ﬁbroblast over time, however, protein levels remained signiﬁcantly
higher than untreated FRDA ﬁbroblasts. Data is represented as the
mean of n= 2 experiments and samples in triplicate. Frataxin is
shown relative to the mean of the normal control is set to 100%. The
error bars represent the s.e.m. Signiﬁcance levels are represented by
asterisks: *Po0.05, **Po0.01 and ***Po0.001.
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of protein oxidation in both ﬁbroblasts was substantially reduced
to ﬁvefold below the level in normal cells (Figure 5), whereas
treatment with the control pHR’SIN-cPPT-SFFV-eGFP-WPRE vector
was not able to achieve this.
FXN gene transfer improves ﬁbroblast recovery after H2O2-
induced oxidative stress
Reduced frataxin expression is accompanied by oxidative stress,
and FRDA cells are also known to be highly sensitive to DNA-
damaging agents such as H2O2.
14 Therefore, we exposed FRDA
and normal human and mouse ﬁbroblasts, together with FRDA
human and mouse cells treated with FXN and eGFP gene transfer,
to increasing concentrations of H2O2 (50, 100, 150 and 200 μM) for
6 h and then subjected the cells to clonogenic assays after
2 weeks of cell growth. Fibroblasts treated with FXN gene transfer
showed a signiﬁcant increase in survival similar to normal
ﬁbroblasts over their non-treated FRDA counterparts (Po0.05)
(Supplementary Figure 4). Using clonogenic cell survival assays,
untreated or LV GFP-treated FRDA ﬁbroblasts subjected to 150 μM
H2O2 had reduced survival compared with normal ﬁbroblasts
(Po0.0001), whereas FRDA ﬁbroblasts treated with LV FXN had an
increase in cell survival closely matching normal ﬁbroblasts
(Supplementary Figure 5).
Genome instability in FRDA cells is reversed following FXN gene
delivery
FRDA cells have been shown to be associated with genome
instability11 and have an impaired ability to repair damaged
nuclear DNA.15 We sought to determine whether the human and
mouse FRDA ﬁbroblasts display genome instability by using
imaging ﬂow cytometry detection and immunocytochemical
detection of γ-H2AX recruitment to DNA DSBs and comparing
the numbers of DSB-positive nuclear foci with the number found
in non-FRDA control ﬁbroblasts. Following staining for γ-H2AX foci
and nuclear DRAQ5 (Shepshed, Leicestershire, UK) staining and
plotting positive foci from images of 10 000–50 000 cells obtained
by imaging ﬂow cytometry, we found human and mouse FRDA
ﬁbroblasts to have approximately twofold more DSBs than normal
control ﬁbroblasts. Treatment of FRDA ﬁbroblasts with FXN gene
transfer reduced the levels of DSBs to that found in control cells
(Figure 6a). These ﬁndings were also conﬁrmed using immuno-
cytochemical detection of γ-H2AX recruitment to DNA DSBs
(Figure 6b). Hence, inherent genome stability in FRDA could be
reversed after FXN gene delivery.
FXN gene delivery restores DNA damage repair in FRDA ﬁbroblasts
Reduced FXN expression is known to impair DNA damage repair.14
We proﬁled the DNA damage-repair response to low level (2 Gy)
γ-irradiation of the human and mouse FRDA ﬁbroblasts and
Figure 3. Localization of intermediate and mature forms of frataxin to subcellular compartments. Western analysis of intermediate and mature
forms of the frataxin protein following cell fractionation was performed on normal, FRDA and LV GFP and LV FXN-treated human (a) and
mouse ﬁbroblasts (b). Frataxin isoforms were identiﬁed using antibodies that recognize the 19 kDa intermediate and 14 kDa mature forms of
the protein (shown by arrows). Controls staining for the mitochondrial fraction used SOD2, for the cytoplasmic fraction used GAPDH and for
the nuclear fraction used EMERIN. Only in the mouse could mature frataxin be identiﬁed in the nuclear fraction (shown by *).
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controls by measuring the recruitment and clearance of the
phosphorylated γ-H2AX histone marker of DSB repair over a 72 h
period when repair is believed to be complete in DNA repair
proﬁcient cells. The proﬁle of DSB repair of control human and
mouse ﬁbroblasts showed an increased γ-H2AX signal to peak at
0.5 h, which then reduced to background levels from 24 h
onwards. The same pattern of repair emerged in human FRDA
cells, but repair was slower, taking up to 72 h to return back to the
original high number of DSB found in FRDA cells (four times that
of normal ﬁbroblasts). A similar pattern of DNA damage repair was
also observed in the FRDA mouse cells. However, in both FRDA
ﬁbroblasts treated with FXN gene transfer, DNA damage-repair
potential was restored, albeit with levels of DSBs slightly higher
than the numbers observed in normal ﬁbroblasts (Figures 7a-c).
DISCUSSION
FRDA pathology is thought to result from defective frataxin
expression, which is primarily caused by GAA repeat expansion
within the ﬁrst intron of the FXN gene leading to its epigenetic
silencing. Being a monogenic disorder, FRDA is amenable to LV
gene therapy, a strategy that offers permanent FXN gene delivery
and integration into the host genome. We used LVs containing the
SFFV promoter not only to determine whether LVs could correct
FRDA at the molecular level, but also to investigate the effect of
high-level FXN expression on cells, which has been previously
reported to be cytotoxic in a Drosophila model of FRDA.18 In this
Drosophila model, high FXN expression was shown to reduce life
span, impair locomotor ability, cause brain damage and even
reduced aconitase activity.
Because it is difﬁcult to obtain patient neurons, FRDA ﬁbroblasts
have been shown to be useful to study FRDA and to test
treatments that reduce oxidative stress, prevent or reverse FXN
methylation and improve cell viability.21–23 In this study, we used
FRDA patient and YG8sR mouse model ﬁbroblasts for gene
transfer of pHR’SIN-cPPT-SFFV-FXN-WPRE frataxin and the
pHR’SIN-cPPT-SFFV-eGFP-WPRE eGFP reporter carrying LVs, which
achieved a virus copy number of around 1 and virtually 100%
infection of human and mouse FRDA ﬁbroblasts. Long-term
LV FXN gene transfer was demonstrated by the fact that vector
copy numbers of both LVs remained constant post infection up to
the 8-week time point investigated. FXN mRNA expression levels,
measured by qRT-PCR were high in the ﬁrst week following
infection and then fell by ~ 50% by week 12 compared with
untreated cells. This was possibly because of shut-down of the
SFFV promoter-driving FXN expression, which has been described
previously for this promoter.25 None-the-less FXN gene expression
still remained signiﬁcantly higher than the levels found in both
untreated FRDA and normal ﬁbroblasts. Levels of frataxin protein
also appeared to follow a similar pattern. Importantly, with this
high-frataxin expression in the treated human and mouse FRDA
cells, population doubling times and cell survival proﬁles were
similar to those found in control ﬁbroblasts, demonstrating that
high-frataxin expression can be achieved without adverse side
effects and supporting the potential for FRDA gene therapy using
LV-mediated FXN delivery. This is further supported by a recent
study that showed correction of cardiac hypertrophy in the Mck
conditional knockout mouse model by AAV-mediated FXN gene
therapy, where frataxin was overexpressed tenfold over the level
of endogenous frataxin expression without deleterious side effects
in the treated mice.20
Frataxin is important for mitochondrial iron homeostasis; in
particular for the de novo biosynthesis of ISCs and its deﬁciency
Figure 4. Gene transfer by pHR’SIN-cPPT-SFFV-FXN-WPRE LV improves
aconitase enzyme levels. Aconitase activity in treated and untreated
FRDA ﬁbroblasts was normalized to the activity of the mean of normal
control ﬁbroblasts set at 100%. Following pHR’SIN-cPPT-SFFV-FXN-
WPRE treatment, aconitase activity in human and mouse FRDA
ﬁbroblast reached 103 and 116% of the level in normal ﬁbroblasts,
respectively (n=3). Error bars shown are s.e.m. Signiﬁcance levels are
represented by asterisks: *Po0.05 and **Po0.01.
Figure 5. Reduced oxidative stress in ﬁbroblasts treated by FXN
gene transfer. (a) Human and (b) Mouse. Oxidized proteins as a
measure of oxidative stress (OS) were identiﬁed and quantiﬁed
using the Oxyblot kit. This measures carbonyl groups introduced
into proteins by oxygen-derived free radicals. OS levels were
compared between normal human and mouse ﬁbroblasts,
untreated FRDA ﬁbroblasts and FRDA ﬁbroblasts treated with
either the eGFP or FXN-carrying vectors. In untreated human and
mouse FRDA cells or pHR’SIN-cPPT-SFFV-eGFP-WPRE treated cells,
oxidative stress was 193 and 172%, respectively, (Po0.05) of the
levels found in normal ﬁbroblasts (set at 100%). When the FRDA
cells received pHR’SIN-cPPT-SFFV-FXN-WPRE treatment oxidative
stress was signiﬁcantly reduced is signiﬁcantly (26%). Results are
taken from the average of ﬁve independent experiments. Error bars
represent s.e.m. Signiﬁcance levels are represented by asterisks:
ns= P40.05, ***Po0.001, ****Po0.0001.
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results in lack of function of ISC-dependent proteins, such as
complexes I, II and III of the ETC and the tricarboxylic acid cycle
enzyme aconitase.6 By FXN gene delivery, the activity of this
enzyme was returned to near normal levels in both human and
mouse cells (from 68 and 49 to 103 and 116%, respectively).
Another important consequence of ETC impairment is increased
levels of and sensitivity to oxidative stress by FRDA cells, which
have been shown to be less capable of handling oxidative
insults.6,21 Indeed, oxidative stress was evident in the FRDA
ﬁbroblasts by measurement of oxidized proteins, which was
twofold higher, compared with control ﬁbroblasts. LV-mediated
FXN gene transfer also reduced the level of oxidized proteins
down to around twofold below the oxidative stress levels in
normal ﬁbroblasts and these cells were also able to tolerate
oxidative stress induced by exogenous H2O2 with levels of survival
matching that of controls. This indicates that LV FXN gene transfer
may improve the antioxidative response and may be the reason
for improved genome stability.
The hypothesis that oxidative stress as a result of low-frataxin
expression alone causes neuronal degeneration is still in debate.
Palomo et al.26 suggested neuronal degeneration to be linked to
frataxin expression after induction of frataxin deﬁciency followed
by cell death in neuron-like cells through apoptosis, which is
accompanied by upregulation of p53, PUMA and Bax and
activation of caspase-3. They also showed cell death could be
prevented by interference with p53, caspase inhibitors or FXN
gene transfer.26 Mitochondrial DNA damage is more prone to
oxidative stress, thought to be because of increased available iron
in mitochondria and the generation of hydroxyl free radicals. Low
levels of frataxin have also been shown in yeast to cause arrest in
cell cycle at G2/M that indicates nuclear DNA damage.14 This
increased susceptibility to oxidative stress appears coupled with
reduced capacity for DNA damage repair.15,27,28 However, only a
few of the enzymes or their associated partners involved in DNA
damage repair have been found to require ISCs. Evidence for
impairment for DNA damage repair in FRDA ﬁbroblasts after
ionizing irradiation has previously been shown by its effects on
clonal cell growth.29 Hence, although mitochondrial dysfunction
and oxidative stress are central features of FRDA, impaired DNA
damage repair may also have a role in cell death.
Low levels of frataxin have also been suggested to be
associated with malignancies in a number of FRDA patients and
even the cause of liver tumorigenesis in mice with hepatocyte-
speciﬁc disruption of FXN.30 This observation has, however, been
refuted by the analysis of large FRDA patient cohort data and by
revisiting the liver tumor pathology in the conditional knockout
frataxin mouse model.31 Frataxin has been proposed to be a
tumor suppressor gene by Guccini et al.,32 who showed that
frataxin modulates P53 expression in tumors in response to
hypoxia. Schulz et al.12 and co-workers have shown that frataxin
suppresses tumor formation in a mouse xenograft model and
Chamberlain and Lewis15 have shown that frataxin deﬁciency in
FRDA patients results in increased sensitivity to ionizing radiation
and also frataxin gene delivery can suppress the growth of several
tumor cell lines. Further supporting frataxin in the role of tumor
suppressor is the fact that p53 has been shown to decrease the
level of frataxin mRNA in human kidney HEK293T cells and that
the human frataxin gene proximal promoter contains a p53-
responsive element (p53RE), which is involved in p53-mediated
control of frataxin expression.33 Evidence provided by a yeast
model of FRDA also suggests that increased levels of DNA damage
occurs in FRDA and the absence of frataxin leads to nuclear
damage, chromosomal instability and a greater sensitivity to DNA-
damaging agents.34 In a study on FRDA peripheral blood
mononuclear cells, increased mitochondrial and nuclear DNA
damage also results in changes in gene expression indicative of
genotoxicity stress.13 The accumulation of DNA lesions may
ultimately lead to apoptosis and cell death via p53-mediated
pathways.
During DNA damage repair, DSBs are recognized by the non-
homologous end-joining pathway that activates the PI3-kinase
ataxia telangiectasia mutated (ATM), which in turn phosphorylates
an H2AX histone variant to form γ-H2AX.35 On DNA damage
Figure 6. (a, b) Reversal of genome instability by FXN gene transfer.
(a) Analysis of genome instability via Imagestream ﬂow cytometry
capture of phosphorylated γ-H2AX recruited to DNA DSB seen as
foci in cell nuclei. Mean number of γ-H2AX foci per cell measured by
ImageStream. In both human and mouse primary ﬁbroblasts means
were calculated over three experiments for normal and ﬁve
experiments for FRDA and LV FXN-treated. P-values were calculated
using the single values of each cell of each experiment (n= 28 000
for Human normal GMO7492; n= 40 464 for Human FRDA GMO3665,
and n= 39664 for LV FXN-treated FRDA), (n= 15000 for mouse
normal Y47; n = 19 000 for mouse FRDA YG8sR and n= 23 000 for LV
FXN-treated FRDA). In human cell lines, FRDA ﬁbroblasts with the
mean of 4 showed higher numbers of γ-H2AX foci per cell compared
with normal cells with 2.1 and LV FXN-treated cells with 1.99 foci per
cell. In mouse cell lines, FRDA ﬁbroblast with the mean of 4.5
showed higher numbers of γ-H2AX foci per cell compared with
Normal cells with 2.8 and LV FXN-treated cells with 2.7 foci per cell.
Mean calculated from two independent experiments performed in
duplicate. Error bars show the s.e.m. Signiﬁcance levels are
represented by asterisks: *Po0.05, **Po0.01 and ***Po0.001.
(b) Mean number of γ-H2AX foci per cell measured by immunocy-
tochemistry in human primary ﬁbroblasts, normal ﬁbroblasts
(GMO7492, n= 400), FRDA ﬁbroblasts (GMO3665, n= 400) and
FXN-treated FRDA ﬁbroblasts (GMO3665 n= 400) and mouse primary
ﬁbroblasts, normal ﬁbroblasts (Y47, n= 400), FRDA ﬁbroblasts
(YG8sR, n= 400) and FXN-treated FRDA ﬁbroblasts (YG-FXN
n= 400). In human cell lines, FRDA ﬁbroblast with the mean of 0.9
showed higher numbers of γ-H2AX foci per cell compared with
Normal cells with 0.3 and FXN-treated cells with 0.46 foci per cell. In
mouse cells, FRDA ﬁbroblast with the mean of 1.9 showed higher
numbers of γ-H2AX foci per cell compared with Normal cells with
0.56 and FXN-treated cells with 0.8 foci per cell. Mean calculated
from two independent experiments performed in duplicate. Error
bars show the s.e.m. Signiﬁcance levels are represented by asterisks:
*Po0.05, **Po0.01 and ***Po0.001.
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induction, especially after DSBs, γ-H2AX molecules spread over
tens of kilobases of DNA ﬂanking the break site and once DSB
repair starts, the lesions are removed and the number of γ-H2AX
foci decreases.36,37 This signaling network, therefore recruits the
repair machinery to the DNA lesion to repair it.38 Hence, γ-H2AX
can be used to measure DNA damage and is useful as a marker
of genome instability and DNA damage repair in cells proﬁcient
in non-homologous end-joining pathway repair machinery.
We used immunocytochemical detection of γ-H2AX proteins by
ﬂuorochrome-linked antibodies to quantify and localize DSBs as a
measure of genome instability and DNA damage repair in the
FRDA ﬁbroblasts. Classical γ-H2AX immunostaining allowed the
detection of individual nuclei and number of foci per nucleus and
thus the damage distribution within cells, whereas imaging ﬂow
cytometry enabled rapid measurement of thousands of cells to
provide statistical signiﬁcance of DNA damage and repair after
DSB induction by γ-irradiation. Both image ﬂow cytometry and
immunocytochemistry enabled the identiﬁcation of higher
Figure 7. (a–c) Immunocytochemistry of DNA damage repair in irradiated ﬁbroblasts. Detection of DNA damage repair proﬁle of irradiated
cells by γ-H2AX of recruitment and clearance from DNA DSBs after 0.5, 5, 24, 48, 72 h post 2 Gy irradiation. (a) Human FRDA ﬁbroblasts had a
mean of 0.9 γ-H2AX foci per cell compared with normal cells with 0.3. FXN-treated cells had only 0.46 foci per cell. (b) Mouse FRDA ﬁbroblast
had a mean of 1.9 γ-H2AX foci per cell compared with 0.56 in normal cells and 0.8 γ-H2AX foci in FXN-treated cells. Calculations are from two
independent experiments performed in duplicate. (c) Analysis of genome instability via immunocytochemistry of ﬁxed cells and γ-H2AX foci
per cell (n= 400). Mean calculated from two independent experiments performed in duplicate. Error bars represent s.e.m. Signiﬁcance levels
are represented by asterisks: ns= P40.05, *Po0.05, **Po0.01 and ***Po0.001.
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numbers of DSB in FRDA ﬁbroblasts compared with normal
ﬁbroblasts, albeit at different levels, possibly due to differences in
the sensitivities of the two methods. Once again FXN delivery
reduced the number of γ-H2AX foci to the level found in control
ﬁbroblasts. Furthermore, after γ-irradiation, cells were able to
repair DSBs more proﬁciently after FXN gene transfer, although
not down to the low background levels of DSBs in normal
ﬁbroblasts. This is possibly due to the fact that not all the FRDA
ﬁbroblasts were expressing LV-mediated FXN, as suggested by the
fact that, even though infected cells still contained a vector copy
number of 1, FXN expression reduced by 50% over the 12-week-
period when DSB foci were measured.
Interestingly, we found oxidative stress levels of FRDA cells were
twofold less than that of control ﬁbroblasts after gene transfer,
pointing to the possibility that frataxin may be important for DNA
damage repair or as mentioned this may be because of an
improvement of the antioxidative response provided by FXN
delivery. To determine whether this is the case, clones of LV-
infected cells would need to be isolated and further characterized
for FXN expression and DSB repair simultaneously. Cells could also
be grown in the presence of antioxidants followed by measure-
ment of the DNA response to irradiation. It would also be
interesting to measure changes in the expression of genes
associated with antioxidants and especially Nrf2 as previously
described in the YG8sR mouse model.39
We conclude that because HIV-1-based LVs are ideal for
neuronal targeting40 and do not cause genotoxicity in mice,41
along with our recent ﬁndings that LVs can efﬁciently reach the
mouse cerebellum and dorsal root ganglia using a reporter gene
(unpublished data), the data presented in this study supports
future efforts to use pHR’SIN-cPPT-SFFV-FXN-WPRE LV to correct
the FRDA-like phenotype in the YG8sR mouse model. It would also
be useful to perform this work in a human sensory neuronal
model reprogrammed from induced pluripotent stem cells that
would enable further investigations of the role of oxidative stress
and genome instability in neuronal degeneration.
MATERIALS AND METHODS
Construction and propagation of a LV carrying the frataxin gene
The plasmid, pTLX1 containing the 1505 bp frataxin open reading frame
(GenBank: U43747.1)42 was subjected to PCR to amplify the FXN gene
using the forward primer 5′-TCGGGATCCGCTCCGGAGCATGTGGACTC-3′
designed with a BamHI site 5′ to the start codon, and the reverse primer 5′-
AGTCTCGAGGTAGCATCAAGCATCTTTTCCGG-3′ that incorporated a XhoI
site 3′ to the gene stop codon. The PCR amplicons were TA cloned into the
pCR2.1-TOPO (K4500-02, Invitrogen Life technologies, Paisely, Renfrew-
shire, UK) vector and sequenced (Beckman Coulter Genomics, Takely,
Essex, UK). The FXN gene was then excised as a BamHI–XhoI fragment and
ligated into the pHR’SIN-cPPT-SFFV-MCS-WPRE LV to generate pHR’SIN-
cPPT-SFFV-FXN-WPRE, which was sequenced. The pHR’SIN-cPPT-SFFV-FXN-
WPRE LV drives FXN using a strong internal SFFV promoter. The vector has
SIN LTR conﬁguration to avoid upregulation of genes located near to the
insertion site (Figure 8). To generate pHR’SIN-cPPT-SFFV-FXN-WPRE
particles, HEK293T cells were transfected with three plasmids: pHR’SIN-
cPPT-SFFV-FXN-WPRE, pMD.G2 carrying the coding sequence for the VSV-G
envelope glycoprotein43 and the packaging plasmid pCMVΔR8.74 carrying
the gag, pol and rev genes as previously described.44,45 In parallel, the
vector pHR’SIN-cPPT-SFFV-eGFP-WPRE that expressed eGFP in infected
cells was also produced in HEK292T cells. Both LV vectors are SIN
conﬁguration, and carry the woodchuck hepatitis virus post-transcriptional
regulatory element (WPRE).46 Brieﬂy, 1.5 × 107 HEK293T cells per T-150 ﬂask
were transfected with 40 μg of the LV constructs, 17.5 μg of pMD.G2 and
32.5 μg of the pCMVΔR8.74 packaging plasmid. Complexes were produced
with 0.25 mM polyethyleneimine (Sigma-Aldrich, Dorset, UK) in Opti-MEM
(Invitrogen, Life technologies, Paisely, Renfrewshire, UK) and incubated at
room temperature for 20–30 min before transfection for 6 h at 37 °C in a
5% CO2 incubator, followed by replacing the medium with DMEM
supplemented with 10% FBS. LVs were collected 48 and 72 h post
transfection. Virus supernatants were initially cleared of cell debris by low-
speed centrifugation (1500 r.p.m., 5 min), ﬁltered through a 0.45-μm ﬁlter
(Millipore, Watford, Hertfordshire, UK) and concentrated 100-fold by
ultracentrifugation at 90 000 g for 90 min at 4 °C (Beckman Coulter, Takely,
Essex, UK). Virus pellets were re-suspended in serum-free medium,
aliquoted and stored at − 80 °C.
LV was titrated using Lenti-X qRT-PCR (Clontech, Mountain View,
CA, USA) and Quant-X One-Step qRT-PCR SYBR (Clontech, California,
USA) kits against the internal serially diluted viral RNA stock supplied with
the kit, as per manufacturer’s instructions. The titer of vector particles
obtained was corrected after calculating LV infectivity coefﬁcients using
eGFP-positive infection of HEK293T cells. Serially diluted pHR’SIN-cPPT-
SFFV-GFP-WPRE LV was used to infect HEK293T cells and infectious titer
was determined using Imagestream ﬂow cytometry (X Merk- Millipore,
Darmstadt, Germany) for eGFP. LV RT titer:Imagestream titer ratios were
calculated by dividing the qRT-PCR vector genome copies per ml by the
infectious particles per ml values. This coefﬁcient was used for pHR’SIN-
cPPT-SFFV-FXN-WPRE titration, which was generated in parallel to pHR’SIN-
cPPT-SFFV-eGFP-WPRE. Virus titers of 1 × 108 infectious particles per ml for
both LV FXN and LV GFP were obtained in this way.
Cell culture
Human primary ﬁbroblasts from FRDA patients and controls (GM03665 and
GM07492, respectively) were obtained from Coriell Cell Repository
(Camden, New Jersey, USA), and primary ﬁbroblasts from YG8sR FRDA
mice and Y47R control mice and were isolated as previously described.5,47
YG8sR cells carry a 120 GAA repeat in intron 1 of the human FXN transgene
resulting in reduced FXN levels to 25% of normal. All experiments were
performed on cells before passage 8. Cells were cultured with Dulbecco’s
modiﬁed essential medium (DMEM) supplemented with GlutaMAX
(Invitrogen life technologies, Paisely, Renfrewshire, UK) plus 10% fetal
bovine serum (FBS) (Invitrogen, Life technologies) and penicillin
(100 U ml− 1) and Streptomycin (100 U ml− 1) (Invitrogen) in a humidiﬁed
chamber at 37 °C and 5% CO2.
LV infectivity and copy number analysis in FRDA human and
mouse model ﬁbroblasts
Infectivity of FRDA human and YG8sR mouse ﬁbroblasts was established
following two rounds of infection by pHR’SIN-cPPT-SFFV-eGFP-WPRE LVs at
an multiplicity of infection of 10. Positive eGFP expressing cells were
identiﬁed by light microscopy under UV light and by imaging ﬂow
cytometry (see below). Measurements of eGFP expression were taken at
48 h and 8 weeks post infection. High level of eGFP-positive cells was
obtained from both human and YG8sR mouse FRDA ﬁbroblasts reaching
close to 100%. Cells were next exposed to pHR’SIN-cPPT-SFFV-FXN-WPRE
at the same multiplicity of infection. Genomic DNA was extracted from
cells infected with pHR’SIN-cPPT-SFFV-eGFP-WPRE and pHR’SIN-cPPT-SFFV-
FXN-WPRE and puriﬁed using the phenol chloroform method.48 Quanti-
tative PCR was performed by an ABI 7700 Sequence Detection System (ABI,
Applied Biosystems, Flow City, CA, USA) using 5′-TGTGTGCCCGTCTGTT
GTGT-3′ and 5′-GAGTCCTGCGTCGAGAGAGC-3′ oligonucleotide primers
and TaqMan probe (FAM) 5-CGCCCGAACAGGGACTTGAA-3′ (TAMRA)
speciﬁc for the viral woodchuck hepatitis regulatory element (WPRE)
sequence contained in each LV.46 The pHR’SIN-cPPT-SFFV-FXN-WPRE
plasmid was used to generate a standard curve of known copy number
by serial (1:10) dilution in siliconized tubes over the appropriate
concentration range to achieve a reliable standard curve for each
measured copy number. Five replicates per spiked sample was PCR-
Figure 8. Schematic representation of pHR’SIN-cPPT-SFFV-FXN-
WPRE. The pHR’SIN-cPPT-SFFV-FXN-WPRE vector is self-inactivating
(SIN) conﬁguration with a WPRE and an internal spleen focus-
forming virus promoter-driving FXN gene expression. VSV-G
pseudotyped pHR’SIN-cPPT-SFFV-FXN-WPRE was generated by
HEK293T cells to a titer of 1 × 108 TU ml− 1 for infecting FRDA
ﬁbroblasts.
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ampliﬁed over the complete standard-curve range. In addition, LV copy
numbers in infected cells were also measured using q-PCR on genomic
DNA from the sample and comparing Ct values of this sample against the
known copy number sample of a clonal sample used to make a diluted
standard curve.49
Measurement of population doubling
Cell population doubling (PD) calculations were performed to determine
their growth rates as described previously.50 Brieﬂy, 5 × 105 cells were
− seeded per 10 cm cell culture dish and counted at each passage. The
following equation:
PD ¼ Log final cell numberð Þ
Log 2
-
Log initial cell numberð Þ
Log 2
was used to determine PD:
Clonogenic cell survival assay
Cultured cells were split, counted by haemocytometer and 100–1000 cells
were plated per 10 cm dish and incubated for 2 weeks at 37 °C 5% CO2.
Cells were stained with 1% methylene blue and the number of colonies
counted. This procedure also followed LV and H2O2 treatments. For
oxidative stress assay, cells were treated with H2O2 (150 μM) for 6 h after
plating. Surviving cells are expressed as a percentage of the survival of
untreated cells.
qRT-PCR of frataxin expression
Total RNA was extracted from homogenized cells in Trizol reagent
(Invitrogen) and quantiﬁed using a NanoDrop 1000 spectrophotometer
(Thermo Fisher Scientiﬁc, Hemel Hempstead, UK) at 260 nm and mRNA
was reverse-transcribed to cDNA using SuperScript III (Invitrogen). Frataxin
gene expression of LV-infected and uninfected control cells was quantiﬁed
by SYBR Green (Applied Biosystems) qRT-PCR in an ABI7900 machine using
FRT-I 5′-TTGAAGACCTTGCAGACAAG-3′ and RRT-II 5′-AGCCAGATTTGC
TTGTTTGG-3′ primers recognizing both human and mouse FXN. The
GAPDH or GAPDH housekeeping genes were used for normalization with
human-speciﬁc primers GAPDH-hF: 5′-GAAGGTGAAGGTCGGAGT-3′ and
GAPDH-hR: 5′-GAAGATGGTGATGGGATTTC-3′ or mouse-speciﬁc primers
GAPDHmF: 5′-ACCCAGAAGACTGTGGATGG-3′ and GAPDHmR: 5′-GGATG
CAGGGATGATGTTCT-3′.
Frataxin protein extraction and quantiﬁcation
Frataxin protein was extracted as previously described42 and the
concentration was determined using the BCA Protein Assay Reagent Kit
(Thermo Fisher Scientiﬁc, Hemel Hempstead, UK). The lateral ﬂow
immunoassay (MitoSciences, North West, WA, USA) was performed as
per manufacturer’s instructions.51 Brieﬂy, 25 μg of extracted cell protein
and buffers were added to wells of a 96-well plate pre-prepared with gold-
conjugated anti-frataxin monoclonal antibody (mAB). After mixing
samples, a ‘dipstick’ assay was used to immunocapture frataxin onto
designated capture zones on the dipstick. Zones representing on frataxin
levels were used to quantify protein with a Hamamatsu immunochromato
reader (MS1000 Dipstick reader, Hertfordshire, UK). Absorbance values
were normalized with control goat α-mouse IgG band (internal positive
control) to correct for protein concentration. Data is expressed as
percentage averages of the controls run on the same assay.52
Localization of intermediate and mature forms of frataxin to
subcellular compartments
Separation of cytosolic, mitochondrial and nuclear fractions was performed
using a cell fractionation kit (Abcam, Milton, Cambridge, UK) following the
manufacturer’s recommendations. Brieﬂy, human and mouse ﬁbroblast
cells were grown in T75 tissue culture ﬂasks to conﬂuency. After cell
trypsinisation and centrifugation, each subcellular fraction was used for the
identiﬁcation of the intermediate and mature forms of frataxin by
measuring these in the protein isolates. Buffer A was used to wash cells,
followed by resuspension to a concentration of 6.6 × 106 cells per ml.
Cellular extractions were obtained after two sequential detergent-
extraction steps. The purity of each fraction was assessed by Western
blotting against GAPDH (cytoplasmic), SOD2 (mitochondrial) and Emerin
(nuclear) proteins. The following antibodies were used for western
blotting: an anti-frataxin monoclonal antibody (1:100, MAB1594, Millipore),
mouse monoclonal anti-GAPDH antibody (1:2000, ab9484, Abcam), mouse
monoclonal anti-SOD2 antibody (1:1000, ab16956 Abcam), mouse mono-
clonal anti-Emerin antibody (1:1000, NCL-Emerin, Leica Biosystems, Milton
Keynes, UK) and a rabbit anti-mouse IgG HRP conjugated secondary
antibody (1:2000, ab97046, Abcam). Detection was performed using the
chemiluminescent reagent (Bio-Rad, Herfordshire, UK) and bands were
visualized using the Molecular Imager Gel Doc XR+ system (Bio-Rad),
and densitometry was carried out using Image Lab 4.1 analysis software
(Bio-Rad).
Aconitase assay
Whole-cell extracts were obtained by homogenization of cultured cells in
50 mM Tris–HCl, pH 8, 10% (v/v) glycerol, 5 mM EDTA, 150 mM KCl, 1 mM
phenylmethylsulfonyl ﬂuoride. Insoluble material was removed by
centrifugation at 10 000 g at 4 °C for 10 min.42 Aconitase activity was
measured using an Aconitase Assay Kit (Cayman Chemical, Ann Arbor,
MI, USA). 50 μl whole-cell lysates were added to 200 μl of substrate mix,
(50 mM Tris/HCl pH 7.4, 0.4 mM NADP, 5 mM Na citrate, 0.6 mM MgCl2, 0.1%
(v/v) Triton X-100 and 1 U isocitrate dehydrogenase) then the reaction was
initiated by adding 50 μl of diluted substrate solution followed by
incubation at 37 °C for 15 min. Absorbance was monitored by spectro-
photometry every minute for 15 min at 340 nm 37 °C to determine the
reaction slope. Aconitase activities of cells were then normalized to citrate
synthase activities, which were determined using a citrate synthase assay
kit (SIGMA, CS0720), as previously described.53
Measurement of oxidative stress in FRDA and control ﬁbroblasts
Protein lysates were prepared as previously described54 and concentration
was determined using the Pierce BCA assay kit (Fischer Scientiﬁc,
Loughborough, UK). Proteins were then modiﬁed by the use of the
OxyBlot Protein Oxidation Detection Kit (Merk-Millipore, Watford, UK),
which measures carbonyl groups introduced into proteins by oxygen-
derived free radicals. Oxidation levels were measured according to the
manufacturer’s protocol. Brieﬂy, protein samples were diluted with lysate
buffer so that 30 μg of protein was present in a ﬁnal 15 μl volume. The
protein sample was denatured by adding 15 μl of 12% SDS and then split
into two 10 μl aliquots, each containing 10 μg of protein. One aliquot was
derivatized with 10 μl of DNPH, whereas the other was used as a negative
control sample and 10 μl of derivatisation-control solution was added
instead. The derivatisation reaction was performed at room temperature
for 15 min, and stopped by adding 7.5 μl of neutralization solution to both
aliquots. The derivatized proteins were separated using 12% SDS-PAGE
and transferred to nitrocellulose. The primary antibody against
2,4-dinitrophenol (rabbit anti-DNP, 1:150 dilution) was added to the
membrane and incubated for 1 h at room temperature. The primary
antibody was removed and the membrane was incubated in secondary
antibody (goat anti-rabbit IgG, 1:300 dilution) for 1 h at room temperature.
Detection was performed using the chemiluminescent reagent (Bio-Rad)
and bands were visualized using the Molecular Imager Gel Doc XR+ system
(Bio-Rad), and densitometry was carried out on the entire column using
Image Lab 4.1 analysis software (Bio-Rad).
Measurement of eGFP gene expression in FRDA ﬁbroblasts
To determine eGFP expression, live cells were analyzed after pHR’SIN-cPPT-
SFFV-eGFP-WPRE LV gene transfer by microscopy using a JuLI Smart
Fluorescent Cell Analyser microscope (Ruskinn Technology, Sanford,
ME, USA). Magniﬁcation (10× ) was used for viewing eGFP expression
under UV light (488 nm excitation and an emission at 520 nm). Using
Image J software (Besthesda, MD, USA), acquired images were merged and
the numbers of eGFP-positive cells were analyzed. Cells expressing eGFP
were also analyzed using imaging ﬂow cytometry. Cells were trypsinized,
washed with ice-cold PBS and ﬁxed with 4% paraformaldehyde. Fixed cells
were then applied to imaging ﬂow cytometry using the Imagestream
system (Amnis Inc.). This permits image capture of each cell in ﬂow using a
maximum of six optical channels. Using the Inspire data acquisition
software (Amnis Inc.), images of ~ 10 000 cells were captured on channel 1
for brightﬁeld (BF) to observe cell morphology, on channel 2 for eGFP
emission and on channel 5 for blue DRAQ5 (D5) nuclear staining. Following
excitation with a 488 nm laser at a power setting of 70 mW, all images
were captured using a 40 ×objective.
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Analysis of cell images and DNA double strand break foci
Nuclear foci positive for γ-H2AX staining were quantiﬁed using ~ 10 000–
50 000 images of cells captured in the Inspire imaging ﬂow cytometry
software (Merk-Millipore, Darmstadt, Germany). Foci were quantiﬁed as
previously described.55 In brief, a series of simple building blocks were
used to ﬁrst identify and gate single cells, then a region was drawn to
identify those single cells that are in the correct focal plane during imaging
ﬂow. Next, two ‘truth’ populations were identiﬁed containing images of
cells that had either few foci (o5) or a large number of foci (48–10).
These populations were then used by the Ideas software (Merk-Millipore)
to enumerate all of the foci in the 10 000–50 000 cells for each cell batch
under analysis.56
Immunocytochemical detection of DNA damage and repair
Immunocytochemical detection of γ-H2AX. A total of 1 × 103 cells were
grown on glass slides then washed with ice-cold PBS, followed by ﬁxation
in 4% paraformaldehyde for 15 min. 0.2% Triton X-100 (Fisher Scientiﬁc,
Loughborough, UK) was used to permeabilize cells for 10 min at 4 °C
followed by the addition of blocking buffer (0.1 g BSA in 50 μl Triton X-100
and 50 ml PBS) to block for 1 h. After humidifying the paraﬁlm covered
slides in a dark box and removal of the blocking buffer, cells were
incubated with primary antibody solution consisted of an anti-phospho-
histone H2AX (serine 139), mouse monoclonal IgG1 antibody (clone
JBW301, Millipore) (1:1000) in blocking buffer. Excess primary antibody was
removed by washing three times for 5 min in TBST solution (8.8.grams of
NaCl+0.2 g of KCL+3g of tris base+500 μl tween 20 in 1 l of dH2O. pH 7.4),
followed by incubation for 1hr at RT in a secondary antibody solution
consisting of an Alexa Fluor 488 rabbit anti-mouse IgG antibody
(Invitrogen) (1:1000) in blocking buffer. Slides were each washed three
times for 5 min in TBST and then 3 times for 5 min in PBS before being de-
hydrated in ethanol (70, 90 and 100%) for 3 min each time. After air drying
15 μl of mounting medium containing DAPI (Invitrogen) was added to
each slide and covered with a cover slip (Fisher scientiﬁc) and sealed using
clear nail varnish.57,58 Images acquisition was performed at RT using a Zeiss
Axioplan 2 microscope equipped with a × 100 ZEISS Plan-NEOFLUAR 1.3 Oil
objective lens and a Zeiss Axiocam color camera (Cambridgeshire, UK)
under the control of AXIOVISION 4.2 software. Images used for comparison
between different treatments and/or cell lines were acquired with the
same instrument settings and exposure times.59
Multispectral imaging ﬂow cytometry detection of γ-H2AX. Imaging ﬂow
cytometry was performed using the Imagestream system (Amnis Inc.).
Using the Inspire data acquisition software, images of 10 000–50 000 cells
were captured on channel 1 for BF, on channel 2 for Alexa Fluor 488 (AF),
representing the green staining of γ-H2AX foci, and on channel 5 for
DRAQ5 nuclear staining. Following excitation with a 488 nm laser at a
power setting of 75 mW, all images were captured using a 40x objective.
Cell classiﬁers were applied to the BF channel to capture objects that
ranged between 50 and 300 units on an arbitrary scale, which was
established from previous studies.56 Image compensation was accom-
plished on untreated cells and those irradiated with 2 Gy γ-irradiation. Cells
that were stained with antibody only or DRAQ5 only were used for
producing the compensation matrix. Images were collected without BF to
capture ﬂuorescence intensity with the 488 nm laser as the single source of
illumination. The Ideas software compensation wizard generates a table of
coefﬁcients whereby detected light that is displayed by each image is
placed into the proper channel (channel 2 for antibody staining and
channel 5 for DRAQ5) on a pixel-by-pixel basis. All coefﬁcients were
normalized to 1 and each coefﬁcient represents the leakage of ﬂuorescent
signal into adjacent channels. Calculated compensation values were
applied to all subsequent analyses as appropriate.56
Irradiation of cells to generate DSBs
To induce DNA DSB and subsequent γ-H2AX foci induction, cells were
grown overnight as proliferating monolayers on poly-prep glass slides
coated with poly-L-lysine (Sigma) in eight-well glass chamber slides
(Labtek, Brendale, Australia). Slides from each sample were created as un-
irradiated controls and the remaining slides were irradiated with 2 Gy
γ-radiation from a Cobalt-60 source (Puridec Technologies, Chesham, UK)
sited at a distance of 25 cm with a dose rate of 0.9 Gy min− 1. The cells
were returned to the incubator and incubated as detailed previously.
γ-H2AX foci were counted in untreated cells and those irradiated with 2 Gy
gamma radiation at 30 min, 5, 24, 48 and 72 h post-irradiation.
Statistical analysis
All other data were analyzed by the Student’s t-test, with a signiﬁcance
value set at Po0.05.
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